**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 74650

**Manuscript Type:** MINIREVIEWS

**Who to screen and how to screen for celiac disease**

Singh P *et al*. Screening for CeD

Prashant Singh, Achintya Dinesh Singh, Vineet Ahuja, Govind K Makharia

**Prashant Singh,** Department ofGastroenterology, University of Michigan, Ann Arbor, MI 48109, USA

**Achintya Dinesh Singh,** Department of Medicine, Cleveland Clinic, Cleveland, OH 44195, USA

**Vineet Ahuja, Govind K Makharia,** Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi 110029, India

**Author contributions:** Singh P and Makharia GK were involved in review concept and the article structure; Singh P, Singh AD were involved in data collection and writing the first draft of the manuscript; All the authors contributed in reviewing and editing the final draft of the manuscript.

**Corresponding author: Govind K Makharia, MBBS, MD, DM, Professor,** Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India. govindmakharia@gmail.com

**Received:** December 31, 2021

**Revised:** March 3, 2022

**Accepted:** June 16, 2022

**Published online:**

**ABSTRACT**

Celiac disease (CeD) is a chronic gluten-induced enteropathy with plethoric manifestations. The typical manifestations of CeD such as chronic diarrhea and malabsorption are widely recognized, however, many patients have atypical manifestations like iron deficiency anemia, idiopathic short stature, hypertransaminesemia or infertility*.* These patients often present to the primary care physicians and/or nongastrointestinal specialties. However, due to a lack of awareness among the healthcare professionals about the various atypical manifestations, many patients are not screened for CeD. In this review, we have summarized the available literature about the prevalence of CeD in various gastrointestinal (chronic diarrhea) and nongastrointestinal conditions (iron deficiency anemia, short stature, cryptogenic hypertransaminesemia, cryptogenic cirrhosis or idiopathic ataxia) where the diagnosis of CeD should be considered. In addition, we also discuss special scenarios where screening for CeD should be considered even in absence of symptoms such as patients with type 1 diabetes, Down’s syndrome, and first-degree relatives of patients with CeD. We discuss the diagnostic performance and limitations of various screening tests for CeD such as IgA anti-tissue transglutaminase antibodies, anti-endomysial antibodies and anti-deamidated gliadin antibodies. Based on the current recommendations, we propose a diagnostic algorithm for patients with suspected CeD.

**Key Words:** Screening; Diagnosis; Serology; High-risk group; Small intestine; Enteropathy

Singh P, Singh AD, Ahuja V, Makharia GK. Who to screen and how to screen for celiac disease. *World J Gastroenterol* 2022; In press

**Core tip:** In this review article, we have summarized the available literature about the prevalence of celiac disease (CeD) in various gastrointestinal (chronic diarrhea) and nongastrointestinal conditions (such as iron deficiency anemia, short stature, cryptogenic hypertransaminesemia, cryptogenic cirrhosis or idiopathic ataxia). We share the various clinical indications for screening for CeD. Also, we elucidate the diagnostic performance of various serological assays along with their limitations and propose an algorithm to diagnose patients with suspected CeD.

**INTRODUCTION**

Celiac disease (CeD) is an immune-mediated enteropathy that affects approximately 0.7% of the world population[1]. The disease is related to a complex interplay between genetic, environmental and host immunity-related factors. It is triggered by ingestion of gluten, a protein present in cereals such as wheat, barley and rye in genetically predisposed individuals. The phenotypic expression of CeD is variable. It ranges from being clinically asymptomatic to severely symptomatic disease[2,3]. Also, CeD once thought to affect only small intestines, is now considered a multisystem disorder. While there is convincing clinical and epidemiological evidence of involvement of organs outside the small intestine, the exact pathogenesis of their involvement remains unexplored. It is likely that HLA-DQ2 restricts gliadin-peptide-induced T-cells that originate in the small intestine, circulate in peripheral blood and home in on other organs, leading to organ-specific cell injury[4,5].

The clinical manifestations of CeD may be related to the gastrointestinal tract, called classical CeD seen in 50%–60% of all cases or nongastrointestinal symptoms called nonclassical CeD accounting for 40%–50% of cases[6,7]. The nonclassic symptoms like short stature anemia, dyspepsia, infertility or hypertransaminesemia could be the sole manifestations of CeD, making clinical diagnosis more elusive. Additionally, CeD can coexist with type 1 diabetes or other autoimmune diseases and its clinical manifestations may remain submerged with the manifestations of primary disease or it may remain clinically silent[8,9].

Because of its diverse manifestations, patients with CeD may present to healthcare professionals other than gastroenterologists or pediatricians such as hematologists with anemia, endocrinologists for short stature or type 1 diabetes, or gynecologists with infertility. The lack of typical manifestations combined with unfamiliarity with the disease lowers the index of suspicion for CeD in such clinical settings. This results in the missed diagnosis of CeD and about 85%–90% of the patients with CeD remain undiagnosed[10-12]. A delay in the diagnosis and institution of appropriate treatment adds to significant morbidity and even mortality in these patients[13].

Over the past two decades, patients with conditions like short stature, iron deficiency anemia and type 1 diabetes, and first-degree relatives have been reported to have a much higher prevalence of CeD compared to the general population[2,14]. Assiduous screening in these conditions can improve the detection of CeD compared to population-based screening for CeD. However, while most gastrointestinal societies agree that there is not enough evidence to recommend screening for CeD in the general population, they offer varying recommendations about which at-risk groups should be routinely screened for CeD[15,16].

In the present review, we summarize the present literature regarding the prevalence of CeD in many conditions to facilitate identification of high-risk groups who could benefit from screening for CeD. We have subgrouped the indications for screening as definitive (when the data to support the screening is robust), probable (when the data to support screening exists but heterogenous) and possible (when there is a biological plausibility, but the evidence is insufficient). Later, we also highlight about the screening strategy for CeD once a decision for screening has been made based on clinical indication.

**Review Methodology**

Relevant studies were searched utilizing Medline, Embase and Scopus databases. Also, additional studies were cross-referenced from the various articles. Studies were identified with the medical subject heading terms and keywords “celiac disease”, “celiac”, “coeliac disease”, “tissue transglutaminase antibody”, “endomysial antibody”, “anti-endomysium antibody”. They were combined using the set operator AND with keywords for relevant medical condition/risk factor (type 1 diabetes mellitus, irritable bowel syndrome, first degree relatives *etc.*). Studies from all languages were reviewed for appropriateness to the clinical question and potentially relevant papers were assessed in detail.

***Terms, definitions and analysis***

For the purpose of this review, CeD is defined as: (1) villous abnormalities of modified Marsh grade 2 on duodenal biopsies along with positive celiac-specific serology [anti-tissue transglutaminase antibody (anti-tTG Ab), anti-endomysial antibody (AEA), anti-deamidated gliadin peptide (anti-DGP Ab) or antigliadin antibody (AGA)]; (2) presence of at least modified Marsh 2 lesions on duodenal histology, along with unequivocal clinical and/or histological response to a gluten-free diet (GFD). Seroprevalence of CeD is defined as the prevalence of positive anti-tTG Ab and/or AEA and/or anti-DGP Ab. Pooled prevalence of CeD in the manuscript refers to pooled prevalence of biopsy-proven CeD.

**Definite indications for screening for CeD**

***Patients with chronic diarrhea***

The classical gastrointestinal symptoms of CeD include chronic or intermittent diarrhea, steatorrhea, abdominal bloating, flatulence, and weight loss[7]. A proportion of patients with CeD may have mild gastrointestinal manifestations such as bowel dysmotility, abdominal pain/discomfort, and bloating, and with this symptom complex, they are can be labelled as having functional gastrointestinal diseases including irritable bowel syndrome (IBS).

One of the classic manifestations of CeD, both in the children and adults, is chronic diarrhea which occurs secondary to diffuse enteropathy and malabsorption. Chronic diarrhea in children is often associated with failure to thrive, irritability and distension of the abdomen. Chronic diarrhea is a predominant manifestation in 43%–85% of patients with newly diagnosed CeD. Conversely, the prevalence of CeD in patients referred to secondary care with chronic diarrhea has been reported to range from 3% to 12.2%[17,18]. Given the high occurrence of CeD in patients with chronic diarrhea and the delay in diagnosis of CeD, several gastroenterology societies such as the American Gastroenterological Association and British Society of Gastroenterology have recommended screening for CeD as first-line investigation in patients with chronic diarrhea[17,19]. Therefore, all patients presenting with chronic diarrhea should be screened for CeD.

***Patients with iron deficiency anemia***

Anemia affects 12%–69% of CeD patients in the western countries and 85%–90% of Indian patients with CeD[20-25]. Iron deficiency anemia (IDA) could be an isolated manifestation of CeD even in the absence of gastrointestinal symptoms.Iron deficiency is the commonest form of anemia in CeD[20,26,27].

In a review including 2998 patients from 18 studies, Mahadev *et al*[14] have reported prevalence of CeD in patients presenting with IDA. Of 2998 patients with IDA included in this meta-analysis, the estimated pooled prevalence of CeD was reported to be 3.2% (95% CI: 2.6%–3.9%). Thus, approximately 1 in 31 patients with IDA have CeD. The authors did not find any relationship between the age and gender of the participants and the prevalence of CeD in patients with IDA. However, the prevalence of CeD in them varied significantly with geographic region. The prevalence of CeD in IDA is significantly higher in Asian countries (4.1% in Turkey and 6.4% in Iran) compared to that in the European countries (2.4%). It is important to note that the prevalence of IDA could vary based on the geographical region and according to the socioeconomic strata of the society[28]. They also found that smaller studies were more likely to report higher prevalence of CeD compared to studies with larger sample size. However, even in larger studies (those including > 200 patients), the pooled prevalence of CeD in patients with IDA was still significantly higher (2.7%) than that in the general population. Thus, the prevalence of CeD in patients with IDA is at-least 2–3 times higher prevalence of CeD than in the general population. Considering the overall high prevalence, all patients with iron deficiency anemia should be screened for CeD.

***Patients with short stature***

The manifestations of CeD start in childhood and hence growth failure/restriction is an important manifestation of CeD. Short stature is more frequent in patients diagnosed during childhood/adolescence than in adulthood. Importantly, institution of GFD in these patients can result in early catch-up growth for the initial 2–3 years[2,29,30]. Early diagnosis and compliance with GFD in patients with CeD result in rapid recovery and patients may achieve normal adult height.

Several studies have estimated the prevalence of CeD in children with idiopathic short stature. We systematically reviewed and meta-analyzed 17 studies and 3759 patients (1582 with all-cause short stature and 2177 with idiopathic short stature), and found that the pooled seroprevalence of CeD based on positive anti-tTG Ab and AEA was 11.2% (95% CI: 4.0%–21.2%) and 9.7% (95% CI: 2.7%–20.2%) for all-cause and idiopathic short stature, respectively. Similarly, pooled prevalence of biopsy-confirmed CeD was 7.4% (95% CI: 4.7%–10.6%) and 11.6% (95% CI: 4.1%–22.2%), for all-cause and idiopathic short stature, respectively[31]. In summary, approximately 1 in 14 patients with all-cause short stature and 1 in 9 patients with idiopathic short stature has biopsy-confirmed CeD. Therefore, all patients with CeD should be screened for CeD.

***Patients with type 1 diabetes***

Because of sharing of genetic susceptibility, especially HLA, type 1 diabetes is often associated with CeD[3,6]. In a systematic review and meta-analysis by Elfström *et al*[32] of 27 studies including 26 605 patients with type 1 diabetes, the pooled prevalence of CeD was 6% (95% CI: 5%–6.9%) of CeD. Thus, more than 1 in 18 patients with type 1 diabetes mellitus have biopsy-proven CeD. The prevalence of CeD in children patients with type 1 diabetes is higher (6.2%, 95% CI: 6.1%–6.3%) than those with adult patients with type 1 diabetes (2.7%, 95% CI: 2.1%–2.3%) (*P* < 0.001). There is no geographical variation and almost a similar prevalence of CeD is reported in type 1 diabetes from all over the world. Therefore, all patients with type 1 diabetes should be screened for CeD[32].

***First-degree relatives of patients with CeD***

Because of sharing of genetic susceptibility, first-degree relatives(FDRs) of patients with CeD are at a higher risk of developing CeD in comparison to the general population. The prevalence of CeD in FDRs of patients with CeD has been extensively investigated and it ranges widely in the literature from 1.6% to 38%[33-35]. Singh *et al*[36] in a systematic review and meta-analysis including 41 studies, has reported 708 CeD patients among 10 252 FDRs suggesting a pooled prevalence of CeD of 7.5% (95% CI: 6.3%–8.8%) in them. Among the FDRs, the risk of having CeD is highest among siblings, followed by offspring and the least in the parents. Daughters and sisters of the CeD patients are at the highest risk (1 in 7 and 1 in 8, respectively) of developing CeD. The risk of developing CeD is 1 in 13 in sons, 1 in 16 in brothers, 1 in 32 in mothers and 1 in 33 in fathers[36]. Most studies reporting prevalence of CeD in FDRs have been cross-sectional and there is a lack of longitudinal studies for assessment of risk of developing CeD over time or over a lifetime. It is still unclear if there is role for repeat screening every few years after an initial negative screening or repeat screening should be reserved for FDRs who develop symptoms. Based on the above-mentioned high-quality data, all FDRs of index patients with CeD should be screened for CeD.

The data on the prevalence of CeD in second-degree relatives (SDRs) of patients with CeD is sparse[37,38]. In a meta-analysis of two eligible studies including 641 SDRs, Weinstein *et al*[39] observed a pooled prevalence of CeD in SDRs to be 2.3% (95% CI: 1.3%–3.8%). The current literature on this topic has several limitations including availability of few studies, small sample size, and high risk of bias. Given these limitations, the magnitude of risk of CeD in SDRs is not clear. Therefore, in view of insufficient data, screening of SDRs of patients with CeD for CeD is not justifiable at the present time.

***Patients with dermatitis herpetiformis***

Dermatitis herpetiformis is among the most common manifestations of CeD and could be the first extraintestinal manifestation to be clinically recognized. It presents as a cluster of intensely pruritic papules and/or vesicles, followed by erosions and excoriations. The most common sites are elbows, knees, scalp, and buttocks, typically along the extensor surface of the upper and lower extremities.

The extent of skin lesions may vary from small area to more diffuse involving many sites at one time[40,41]. Furthermore, these lesions may appear intermittently and may be absent at the time of examination.

The pathognomonic histology with immunohistochemistry or immunofluorescence shows granular IgA deposits and neutrophil infiltrates in the papillary dermis. Almost 85% of these patients with a Caucasian ethnicity carry HLA-DQ2 mutations, while the remainder have HLA-DQ8[42]. Typically, only two thirds of patients with dermatitis herpetiformis have villous abnormalities and one third of them have no enteropathy[43]. A survey of 1138 biopsy-confirmed patients with CeD, found a 9.8% prevalence of dermatitis herpetiformis in patients with CeD[44].

A study from Finland have also shown that 17% of patients with CeD have dermatitis herpetiformis [45]. Therefore, all patients with a diagnosis of dermatitis herpetiformis should be screened for CeD, even in the absence of intestinal manifestations.

***Patients with Down syndrome***

The prevalence of CeD in patients with Down syndrome has been extensively investigated. Based on data from 31 studies including 4383 patients with Down syndrome, a recent meta-analysis reported a pooled prevalence of CeD in them to be 5.8% (95% CI: 4.7%–7.2%)[46]. Prevalence of CeD was higher in the studies including only children with Down syndrome than in those including both adults and children with Down syndrome. The higher prevalence of CeD in Down syndrome is independent of the geographical location as studies from Europe, America and Asia have all shown higher prevalence of CeD among patients with Down syndrome. Based on this high-quality evidence, all patients with Down syndrome should be screened for CeD.

**Probable indications for screening for CeD**

***Patients with liver diseases***

Patients with CeD can have a variety of liver-related manifestations that ranges from elevation of serum transaminases to cirrhosis. Elevated transaminases can be seen in 27% (95% CI: 13%–44%) of newly diagnosed patients with CeD and they normalize in 63% to 90% of patients within 1 year of GFD[47].

***Cryptogenic hypertransaminesemia***

Sainsbury *et al*[47] in a systematic review including six studies has reported a pooled prevalence of biopsy-proven CeD of 3.6% among patients with cryptogenic hypertransaminesemia. In a study of 463 adults with CeD[48], 40.6% patients had elevated AST/ALT levels at the time of diagnosis compared to 24.2% CeD patients after initiation of GFD. The quality of evidence has been considered high due to a large effect size without any significant imprecision. Given the high prevalence of CeD in patients with cryptogenic hypertransaminesemia, and a potential for reversal of serum transaminases level with GFD, it is justifiable to screen patients with cryptogenic hypertransaminesemia for CeD.

***Cryptogenic cirrhosis***

Undetected CeD can lead to persistent liver injury progressing from elevated liver biochemistries to cirrhosis of the liver[49-53]. In one of the early reports, Kaukinen *et al*[52] found a reversal in the hepatic dysfunction after initiation of GFD in four patients awaiting liver transplantation, and eventually, three of them were remitted from the liver transplantation list. In a recent prospective study by Wakim-Fleming *et al*[54], of 204 consecutive patients with biopsy-proven liver cirrhosis, CeD was reported in 2.5%. There was improvement in liver function tests with initiation of GFD in these patients. However, these studies had serious limitations including small sample size (all < 100 subjects), selection bias, imprecision and inconsistent results. Given these limitations, the quality of evidence is poor to suggest a true estimate of prevalence of CeD in cryptogenic cirrhosis. In view of the data of improvement in liver functions with GFD, it may be worthwhile to screen the patients with cryptogenic cirrhosis for CeD.

***Patients with autoimmune hepatitis***

Recently, in a systematic review of eight eligible studies, the prevalence of biopsy-proven CeD was 3.5% (95% CI: 1.6%–5.3%) among 567 individuals with autoimmune hepatitis, which is clearly higher than that in the general populations[55]. However, these studies had serious limitations including small sample size, selection bias, imprecision and inconsistent results. Despite these limitations, we suggest screening for CeD in all patients with autoimmune hepatitis because of the relatively higher pooled prevalence of CeD in these subjects compared to the general population.

***Patients with irritable bowel syndrome***

Patients with CeD may have minor gastrointestinal infection including diarrhea, abdominal pain, and bloating sensation without any definitive manifestations for malabsorption. Such patients are often diagnosed with irritable bowel syndrome (IBS) in general clinical practice, unless screened for CeD. In a study by Irvine *et al*[56]including 22 studies with 6991 patients with IBS, the reported pooled prevalence of CeD was 3.3% (95% CI: 2.3%–4.5%) in them.

The pooled prevalence of CeD in patients with IBS varies significantly with the IBS subtype and their geographical location. The prevalence of CeD is higher in patients with diarrhea-predominant IBS (pooled prevalence 5.4%, 95% CI: 3.3%–7.8%) compared to those with constipation-predominant IBS (1.8%, 95% CI: 0.9%–3.0%) and mixed form of IBS (3.1%, 95%CI: 1.7%–5.1%).

In the above meta-analysis, all but one study was from secondary or tertiary care referral centers. Furthermore, 20 of the 22 studies were from Europe and Asia with pooled prevalence of CeD in patients with IBS in them was 3.9% (95% CI: 2.1%–6.3%) and 3.7% (95% CI: 2.2%–5.6%), respectively. The only study from North America, which also evaluated celiac serology positive individuals with IBS further with duodenal biopsies, did not find an increased prevalence of CeD in patients with IBS. A recent study from Iraq found a prevalence of 5% among 100 patients with IBS[57].

Thus, the utility to screening for CeD in individuals with IBS in primary care settings or the general population remains unclear. Based on available evidence, it may be justifiable to screen patients with diarrhea predominant-IBS and mixed IBS presenting to secondary or tertiary care centers for CeD in Europe and Asia.

***Patients with osteoporosis***

Patients with CeD are at an increased risk for developing varying degrees of osteopenia and osteoporosis. Patients with untreated CeD have low bone mineral density agnostic to the clinical presentation[58,59]. The reported pooled prevalence of osteoporosis and osteopenia is 14.4% (95% CI: 9%–20.5%) and 39.6% (95% CI: 31.1%–48.8%), respectively in 563 premenopausal women and men with CeD[60]. Along with osteoporosis, patients with CeD are also at a higher risk of developing bone fractures. A comparative meta-analysis of 20 995 patients with CeD and 97 777 controls from eight studies published between 2000 and 2007 found that patients with CeD had a 43% higher risk for developing nontraumatic fracture compared with controls[61]. Also a recent study found that patients with newly diagnosed CeD have low bone marrow density and this improves after initiation of GFD[62].

Laszkowska *et al*[63] performed a systematic review and meta-analysis to estimate the prevalence of CeD in patients with osteoporosis. They pooled data on 3188 patients with osteoporosis from eight studies and reported a weighted pooled prevalence of CeD to be 1.6% (95% CI: 1.1%–2.0%). The authors observed a positive correlation between underlying prevalence of CeD in the general population and the prevalence of CeD in osteoporosis suggesting the prevalence of CeD in patients with osteoporosis is higher in the areas with higher prevalence of CeD in the general population. Therefore, the prevalence of CeD does not appear to be significantly higher in patients presenting with osteoporosis than that in the general population. Given these findings, while all individuals with new diagnosis of osteoporosis may not need screening for CeD, however patients with osteoporosis having additional symptoms of CeD such as iron deficiency anemia, chronic diarrhea should be screened for CeD.

**Possible conditions for screening for CeD**

***Patients with dyspepsia***

In a systematic review and meta-analysis, we pooled the data from 19 studies involving 9711 patients with dyspepsia in whom initial screening for CeD was performed either by using celiac serological test (anti-tTG ab or AEA) followed by duodenal mucosal biopsy in seropositive patients or the duodenal mucosal biopsy alone in all eligible patients[64]. The pooled prevalence of CeD has been found to be 1.4% (95% CI: 0.9%–1.8%) in patients with dyspepsia. Another meta-analysis including 10 studies also reported the prevalence of CeD to be 1% in patients with dyspepsia[65]. As the prevalence of CeD in patients with dyspepsia is almost like that in the general population, patients with dyspepsia may not be a higher risk of having CeD. It is, however, still unclear if patients with refractory dyspeptic symptoms are at higher risk of having CeD.

***Women with infertility***

The patients with CeD can delayed menarche, early menopause, recurrent abortions, infertility, intrauterine growth retardation, and low birth weight (preterm and small for gestational age babies)[66,67]. Additionally, reports have suggested that women with infertility have conceived after initiation of GFD with a diagnosis of CeD[68,69]. Furthermore, there are multiple studies reporting the prevalence of CeD in women with infertility in women who had been investigated for the causes of infertility earlier (unexplained or idiopathic infertility) and those women with infertility who were never investigated for infertility (all cause infertility).

***Women with unexplained or idiopathic infertility***

Based on case–control studies, two previous meta-analyses have reported that women with unexplained infertility have 5–6 times increased odds of having CeD compared to the general population[70,71]. However, a recent meta-analysis did not find an increased prevalence of CeD in women with unexplained infertility[72]. They reported a pooled prevalence of 0.6% for biopsy-proven CeD in women with unexplained infertility, which is close to the prevalence of CeD in the general population. Of note, a common limitation of all three meta-analyses is the small sample size of primary studies. Based on the current evidence, it is not clear if all women with unexplained infertility should be screened for CeD or not and more research is needed in this area.

***Women with all-cause infertility***

In a systematic review and meta-analysis, Glimberg *et al*[72] pooled the data from 11 eligible studies including 1617 women with all-cause infertility and found a prevalence of 0.7% (95% CI: 0.2%–1.2%) for biopsy-proven CeD. Based on above-mentioned data, screening women with all-cause infertility for CeD, may not be justified. However, as above, more studies are needed to further explore the prevalence of CeD in women with infertility.

***Patients with idiopathic cardiomyopathy***

There are only a few studies that have systematically explored the prevalence of CeD in patients with idiopathic cardiomyopathy[73-77]. The prevalence of CeD in these studies have ranged from 0% to 5.7%. Most of these studies have limitations including a high risk of bias, small sample size and heterogenous patient population included in these studies. Given these serious limitations in the quality of evidence, the present level of evidence does not support screening of patients with idiopathic cardiomyopathy for CeD. Future studies with better study design, larger sample size and various geographic regions should be undertaken for estimation of risk of CeD in patients with cardiomyopathy.

***Patients with autoimmune thyroid diseases***

In a recent systematic review and meta-analysis, Roy *et al*[78] estimated the pooled prevalence of CeD to be 1.6% (1.3%–1.9%) among 6024 patients with autoimmune thyroid diseases from 15 studies. The review has included even those studies where patients having villous abnormalities of modified Marsh grade 1 and 2 have been included as CeD. When the analysis was restricted to those with villous abnormalities of modified Marsh 3, a pooled prevalence of CeD declined to 1.4% (95% CI: 1.0%–1.8%) in them. The prevalence of CeD was lower in patients with hypothyroidism (1.4%, 95% CI: 1.0%–1.9%) than patients with hyperthyroidism (2.6%, 95% CI: 0.7%–4.4%). The available data do not support that routine screening for CeD will likely not be of benefit for majority of patients with autoimmune thyroid diseases. However, larger studies with rigorous methodology are needed in this area.

***Patients with idiopathic epilepsy***

Several studies have evaluated the prevalence of CeD in patients with idiopathic epilepsy[79–81]. In a systematic review, a pooled prevalence of CeD in patients with idiopathic epilepsy is 2.1% (95% CI: 1.6%–2.6%, *n* = 3389) has been reported[80]. The quality of the studies included in this review have major limitations including high overall risk of bias (which decreases our confidence in the estimate), inconsistency (several studies showing no increased risk while others showing increased risk), and imprecision. Based on the presently available data, screening of patients with idiopathic epilepsy for CeD cannot be recommended. There is a need for multicentric studies including larger sample size for better estimation of risk of CeD in patients with idiopathic epilepsy.

***Patients with idiopathic cerebellar ataxia***

The neurological manifestations of CeD and gluten-related disorders are broad, conditions like ataxia and peripheral neuropathy are well recognized, others such as migraine, epilepsy, dementia, cognitive impairment and depression have also been reported[82–85]. Patients with idiopathic sporadic ataxia and positive for AGAs (either IgG or IgA or both) with or without presence of enteropathy are diagnosed as gluten ataxia[83].

Gluten ataxia commonly presents as a sporadic ataxia and most patients do not have associated enteropathy. A systematic review and meta-analysis have found higher odds of AGA positivity in patients with idiopathic cerebellar ataxia (OR 4.2, 95% CI: 3.1–5.9) as compared to controls[86]. The odds of positive AGAs have not been found to be higher in patients with hereditary ataxia (OR 1.41, 95% CI: 0.82–2.44). Most of the studies included in the review are cross-sectional, and the results show significant imprecision or inconsistency. Considering that treatment response in gluten ataxia would depend on the duration of the ataxia and that GFD may positively impact the ataxia, patients with idiopathic or undiagnosed ataxia should be screened for gluten ataxia using IgG and IgA AGA[87,88].

A very few studies have evaluated presence of CeD in patients in patients presenting with ataxia. In a study by Hadjivassiliou *et al*[89], reported that 24% of patients with gluten sensitivity ataxia had CeD. Pellecchia *et al*[90] found all three patients with a positive IgG AGA to have CeD. Bushara *et al*[91] biopsied seven of the nine patients with gluten sensitivity ataxia and none were diagnosed to have CeD. Small number of patients, high risk of bias and heterogenous results of these studies limit drawing of a robust conclusion. Therefore, based on the available data, no definitive recommendation can be made to screen patients with sporadic and idiopathic ataxia for CeD.

***Patients with dental enamel defects***

Only two studies examined the occurrence of CeD in patients with dental enamel defects[92,93] and in them the prevalence of CeD ranged between 7.7% and 17.8%. In one of these studies, 1 year of GFD resulted in significantly higher reversal of enamel changes in CeD patients compared to those without CeD (48% *vs* 3.4% patients, *P* < 0.001), suggestive of a causal association[92] Despite the relatively higher prevalence estimate of CeD seen in these studies, there is likelihood of some publication bias and these studies had very small sample size.

In two recent case–control studies, patients with CeD had higher dental enamel defects and other oral manifestations like aphthous ulcers were higher compared to controls[94,95]. For these reasons, large-scale community-based studies across different sociocultural and geographical populations need to be undertaken to ensure accounting for confounding factors that influence oral health as well as generalizability of the results. Until such time, screening of adults or children with dental enamel defects for CeD is not clear.

We have summarized the reported prevalence of CeD in the various clinical conditions based on the organ systems in Figure 1 and based on the indication in Table 1.

**How to screen for ceD?**

While there is significant heterogeneity among clinicians in selecting the medical conditions where they screen patients for CeD, there also exists significant variation in selecting the screening tool for CeD. Currently, celiac-specific serological tests are the first-line investigations for screening for CeD. Duodenal biopsies showing villous atrophy, crypt hyperplasia and increase in intraepithelial lymphocytes on a gluten-containing diet continue to be the gold standard for patients with CeD. Given the invasive nature of upper gastrointestinal endoscopy, limited availability in resource limited countries and associated cost, this ‘gold-standard’ can however not be applied to all patients who need to be screened for CeD.

The specific celiac serological tests include IgA anti-tTG Ab, IgA AEA, and IgG anti-DGP Ab. While IgA/IgG AGA has been used in screening for CeD in the past, given their poor specificity and sensitivity, they are no longer recommended to be used for screening for CeD. In the section below, we discuss the utility of three commonly used celiac-specific serological tests for screening for CeD.

***IgA anti-tTG Ab***

Given its widespread availability, ease of performance and lower costs compared to other celiac-specific serological tests, IgA anti-tTG Ab is the most used serological test for screening for CeD. A recent systematic review has shown that pooled sensitivity and specificity of anti-tTG Ab for CeD are 92.8% (95% CI: 90.3%–94.8%) and 97.9% (95% CI: 96.4%–98.8%), respectively. IgA anti-tTG Ab testing should be combined with total serum IgA levels to rule out IgA deficiency which is 10–15 times more common in patients with CeD compared to general population[96]. In patients with IgA deficiency, duodenal biopsies or further serological testing such as IgG- based anti-DGP Ab should be pursued.

Despite their widespread use and high sensitivity, these anti-tTG Ab assays have high interassay variability in their diagnostic performance[97,98]. Although anti-tTG Ab assays are the first-line investigation to screen for CeD, healthcare providers should realize that false-negative rate of a single IgA anti-tTG Ab assay can be over 20% suggesting a single negative IgA anti-tTG Ab assay cannot be relied upon as a sole test to rule out CeD especially if clinical suspicion for CeD is high[97]. In these cases, a negative IgA anti-tTG Ab assay must be followed with duodenal biopsies.

Moreover, the issue of diagnostic performance of these assays is complicated by the fact that there is significant intra-assay variation in the performance of IgA anti-tTG Ab assays in racially and geographically distinct population[98]. Most studies of diagnostic performance of IgA anti-tTG Ab assays (including the manufacturer provided validation studies) are performed in Caucasian populations, and unfortunately, these results cannot be extrapolated to other ethnic populations. However, sensitivity of these assays can be improved without significantly compromising the specificity if receiver operator curve-based cut-offs can be developed for each population. Thus, multi-institutional collaborative workshops at national and international levels using coded and blinded standardized sera from well-defined patients with CeD (with varying levels of titers) and healthy controls are necessary to identify and validate population-specific cut-off values as well as the best performing IgA anti-tTG Ab assays for each population. Till then, diagnostic performance of commonly available anti-tTG Ab assays should be studied at each center performing anti-tTG Ab testing.

Finally, recent guidelines now allow for a diagnosis of CeD to be established without duodenal biopsy in a subset of patients with CeD; on the basis of high levels of anti-tTG Ab [× 10 fold upper limit of normal (ULN)] and positive AEA in a second sample[99]. However, these guidelines are often not interpreted correctly and many healthcare providers interpret low level titers as diagnostic of CeD. Even with anti-tTG Ab titers as high as 10-fold ULN, a confirmatory AEA testing on a second sample might not be obtained given either due to inappropriate interpretation of the guidelines or the lack of availability of AEA testing. This can lead to overdiagnosis’ of CeD as anti-tTG Ab at low titers have poor positive predictive value for CeD. Therefore, there is urgent need for widespread dissemination of diagnostic algorithms and guidelines among primary care physicians, gastroenterologists, and non-gastroenterology specialists.

***AEA***

AEA is an indirect immunofluorescence-based testing requiring rhesus monkey esophagus or human umbilical cord as a substrate. Therefore, it can only be performed in specialized laboratories and is much more labor intensive compared to ELISA. Moreover, they are based on subjective interpretation of the results. Based on a recent systematic review, the pooled sensitivity and specificity of AEA for the diagnosis of AEA were 73.0% (95% CI: 61.0%–83.0%) and 99.0% (95% CI: 98.0%–99.0%), respectively[96]. Given the limitations of the testing described above, AEA is not an ideal screening test for CeD outside of referral centers. Although a positive AEA testing is highly suggestive of CeD (given specificity approaching 100%), a negative AEA should not be relied upon to rule out CeD.

***IgG anti-DGP Ab***

IgG anti-DGP Abs are the latest serological assays for CeD and have been shown to have pooled sensitivity of 87.8% (95% CI: 85.6%–89.9%) and pooled specificity of 94.1% (95% CI: 92.5%–95.5%)[96]. Although pooled sensitivity of IgG anti-DGP Ab assays is high, it is still lower than pooled sensitivity of IgA anti-tTG Ab assay. Furthermore, several studies have shown that isolated IgG anti-DGP Ab in patients with normal serum IgA levels do not increase the yield of the diagnosis of CeD. Therefore, current IgG anti-DGP Ab cannot be used to replace IgA anti-tTG Ab as the first-line strategy to screen for CeD. Its role in CeD diagnosis is as a complementary assay to be used in patients with IgA deficiency (where IgA anti-tTG Ab assays cannot be relied upon).

***Point of care tests***

Recently, point of care tests (POCTs) for CeD have become commercially available in Europe. Studies have reported significant variability in their sensitivity (70%–100%) and specificity (85%–100%). The pooled sensitivity and specificity of all POCTs (based on anti-tTG Ab or anti-DGP Ab or anti-tTG Ab + AGA) for diagnosing CeD has been reported to be 94.0% (95% CI: 89.9%–96.5%) and 94.4% (95% CI: 90.9%–96.5%), respectively[100]. The pooled positive and negative likelihood ratios for POCTs are 16.7 and 0.06, respectively. The pooled sensitivity and specificity for IgA anti-tTGAb based POCTs are 90.5% (95% CI: 82.3%–95.1%) and 94.8% (95% CI: 92.5%–96.4%), respectively. However, this pooled sensitivity appears to be lower compared to standard ELISA based IgA anti-tTG Ab assay. Therefore, wherever available anti-tTG Ab should be used as first line screening test. However, POCTs can be an excellent alternative in areas with limited access to laboratory-based testing. All the above tests are summarized in Table 2.

***Further testing***

Once the screening test is positive in an individual suspected to have CeD, the healthcare professional should follow the suggested guidelines by many professional gastroenterology societies for further evaluation[15,19]. We have suggested a testing schematic for the various indications for suspected CeD in Figure 2.

**CONCLUSION**

There is good evidence to suggest screening of patients with chronic diarrhea, IDA, short stature, dermatitis herpetiformis, type 1 diabetes, Down syndrome, as well as first-degree relatives of CeD. The possible indications for screening of CeD include cryptogenic elevated transaminases, cryptogenic cirrhosis autoimmune hepatitis, IBS, autoimmune thyroid disease, and osteopenia/osteoporosis. There is need for systematic studies for many conditions such as rheumatological diseases, psoriasis, cardiomyopathy, neurological diseases, and liver diseases for the prevalence of CeD in them. Screening for CeD is a well standardized, simple, and relatively inexpensive process and it provides an opportunity for early detection of CeD in them.

**ACKNOWLEDGMENTS**

We acknowledge the support of Department of Biotechnology, Government of India, for creation of Indian Consortium on Celiac Disease and National Celiac Disease Biorepository. We do appreciate the support from Research Section of our institution for facilitating the research on Celiac disease.

**REFERENCES**

1 **Singh P**, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, Kelly CP, Ahuja V, Makharia GK. Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol* 2018; **16**: 823-836.e2 [PMID: 29551598 DOI: 10.1016/j.cgh.2017.06.037]

2 **Nardecchia S**, Auricchio R, Discepolo V, Troncone R. Extra-Intestinal Manifestations of Coeliac Disease in Children: Clinical Features and Mechanisms. *Front Pediatr* 2019; **7**: 56 [PMID: 30891436 DOI: 10.3389/fped.2019.00056]

3 **Jericho H**, Guandalini S. Extra-Intestinal Manifestation of Celiac Disease in Children. *Nutrients* 2018; **10** [PMID: 29895731 DOI: 10.3390/nu10060755]

4 **Lindfors K**, Ciacci C, Kurppa K, Lundin KEA, Makharia GK, Mearin ML, Murray JA, Verdu EF, Kaukinen K. Coeliac disease. *Nat Rev Dis Primers* 2019; **5**: 3 [PMID: 30631077 DOI: 10.1038/s41572-018-0054-z]

5 **Al-Bawardy B**, Codipilly DC, Rubio-Tapia A, Bruining DH, Hansel SL, Murray JA. Celiac disease: a clinical review. *Abdom Radiol (NY)* 2017; **42**: 351-360 [PMID: 28078381 DOI: 10.1007/s00261-016-1034-y]

6 **Lebwohl B**, Sanders DS, Green PHR. Coeliac disease. *Lancet* 2018; **391**: 70-81 [PMID: 28760445 DOI: 10.1016/S0140-6736(17)31796-8]

7 **Ludvigsson JF**, Leffler DA, Bai JC, Biagi F, Fasano A, Green PH, Hadjivassiliou M, Kaukinen K, Kelly CP, Leonard JN, Lundin KE, Murray JA, Sanders DS, Walker MM, Zingone F, Ciacci C. The Oslo definitions for coeliac disease and related terms. *Gut* 2013; **62**: 43-52 [PMID: 22345659 DOI: 10.1136/gutjnl-2011-301346]

8 **Lundin KE**, Wijmenga C. Coeliac disease and autoimmune disease-genetic overlap and screening. *Nat Rev Gastroenterol Hepatol* 2015; **12**: 507-515 [PMID: 26303674 DOI: 10.1038/nrgastro.2015.136]

9 **Medical Advisory Secretariat**. Clinical utility of serologic testing for celiac disease in asymptomatic patients: an evidence-based analysis. *Ont Health Technol Assess Ser* 2011; **11**: 1-63 [PMID: 23074415]

10 **Choung RS**, Larson SA, Khaleghi S, Rubio-Tapia A, Ovsyannikova IG, King KS, Larson JJ, Lahr BD, Poland GA, Camilleri MJ, Murray JA. Prevalence and Morbidity of Undiagnosed Celiac Disease From a Community-Based Study. *Gastroenterology* 2017; **152**: 830-839.e5 [PMID: 27916669 DOI: 10.1053/j.gastro.2016.11.043]

11 **Riznik P**, De Leo L, Dolinsek J, Gyimesi J, Klemenak M, Koletzko B, Koletzko S, Korponay-Szabó IR, Krencnik T, Not T, Palcevski G, Sblattero D, Vogrincic M, Werkstetter KJ, Dolinsek J. Diagnostic Delays in Children With Coeliac Disease in the Central European Region. *J Pediatr Gastroenterol Nutr* 2019; **69**: 443-448 [PMID: 31219933 DOI: 10.1097/MPG.0000000000002424]

12 **Catassi C**, Gatti S, Fasano A. The new epidemiology of celiac disease. *J Pediatr Gastroenterol Nutr* 2014; **59** Suppl 1: S7-S9 [PMID: 24979197 DOI: 10.1097/01.mpg.0000450393.23156.59]

13 **Lebwohl B**, Green PHR, Söderling J, Roelstraete B, Ludvigsson JF. Association Between Celiac Disease and Mortality Risk in a Swedish Population. *JAMA* 2020; **323**: 1277-1285 [PMID: 32259229 DOI: 10.1001/jama.2020.1943]

14 **Mahadev S**, Laszkowska M, Sundström J, Björkholm M, Lebwohl B, Green PHR, Ludvigsson JF. Prevalence of Celiac Disease in Patients With Iron Deficiency Anemia-A Systematic Review With Meta-analysis. *Gastroenterology* 2018; **155**: 374-382.e1 [PMID: 29689265 DOI: 10.1053/j.gastro.2018.04.016]

15 **Rubio-Tapia A**, Hill ID, Kelly CP, Calderwood AH, Murray JA; American College of Gastroenterology. ACG clinical guidelines: diagnosis and management of celiac disease. *Am J Gastroenterol* 2013; **108**: 656-76; quiz 677 [PMID: 23609613 DOI: 10.1038/ajg.2013.79]

16 **Al-Toma A**, Volta U, Auricchio R, Castillejo G, Sanders DS, Cellier C, Mulder CJ, Lundin KEA. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. *United European Gastroenterol J* 2019; **7**: 583-613 [PMID: 31210940 DOI: 10.1177/2050640619844125]

17 **Arasaradnam RP**, Brown S, Forbes A, Fox MR, Hungin P, Kelman L, Major G, O'Connor M, Sanders DS, Sinha R, Smith SC, Thomas P, Walters JRF. Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition. *Gut* 2018; **67**: 1380-1399 [PMID: 29653941 DOI: 10.1136/gutjnl-2017-315909]

18 **Panezai MS**, Ullah A, Ballur K, Gilstrap L, Khan J, Tareen B, Kakar M, Khan J, Rasheed A, Waheed A, Ghleilib I, White J, Cason FD. Frequency of Celiac Disease in Patients With Chronic Diarrhea. *Cureus* 2021; **13**: e20495 [PMID: 35047307 DOI: 10.7759/cureus.20495]

19 **Husby S**, Murray JA, Katzka DA. AGA Clinical Practice Update on Diagnosis and Monitoring of Celiac Disease-Changing Utility of Serology and Histologic Measures: Expert Review. *Gastroenterology* 2019; **156**: 885-889 [PMID: 30578783 DOI: 10.1053/j.gastro.2018.12.010]

20 **Harper JW**, Holleran SF, Ramakrishnan R, Bhagat G, Green PH. Anemia in celiac disease is multifactorial in etiology. *Am J Hematol* 2007; **82**: 996-1000 [PMID: 17636474 DOI: 10.1002/ajh.20996]

21 **Halfdanarson TR**, Litzow MR, Murray JA. Hematologic manifestations of celiac disease. *Blood* 2007; **109**: 412-421 [PMID: 16973955 DOI: 10.1182/blood-2006-07-031104]

22 **Haapalahti M**, Kulmala P, Karttunen TJ, Paajanen L, Laurila K, Mäki M, Mykkänen H, Kokkonen J. Nutritional status in adolescents and young adults with screen-detected celiac disease. *J Pediatr Gastroenterol Nutr* 2005; **40**: 566-570 [PMID: 15861017 DOI: 10.1097/01.mpg.0000154658.16618.f9]

23 **Howard MR**, Turnbull AJ, Morley P, Hollier P, Webb R, Clarke A. A prospective study of the prevalence of undiagnosed coeliac disease in laboratory defined iron and folate deficiency. *J Clin Pathol* 2002; **55**: 754-757 [PMID: 12354801 DOI: 10.1136/jcp.55.10.754]

24 **Singh P**, Arora S, Makharia GK. Presence of anemia in patients with celiac disease suggests more severe disease. *Indian J Gastroenterol* 2014; **33**: 161-164 [PMID: 24243078 DOI: 10.1007/s12664-013-0423-1]

25 **Dahele A**, Ghosh S. Vitamin B12 deficiency in untreated celiac disease. *Am J Gastroenterol* 2001; **96**: 745-750 [PMID: 11280545 DOI: 10.1111/j.1572-0241.2001.03616.x]

26 **Bodé S**, Gudmand-Høyer E. Symptoms and haematologic features in consecutive adult coeliac patients. *Scand J Gastroenterol* 1996; **31**: 54-60 [PMID: 8927941 DOI: 10.3109/00365529609031627]

27 **Jansson-Knodell CL**, Rubio-Tapia A. Case Finding for the Pale Celiac Patient: New Iron Deficiency Anemia Guidelines Missing Many Anemic Celiacs? *Gastroenterology* 2021; **160**: 2617-2618 [PMID: 33387513 DOI: 10.1053/j.gastro.2020.10.063]

28 **Kassebaum NJ**, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, Regan M, Weatherall D, Chou DP, Eisele TP, Flaxman SR, Pullan RL, Brooker SJ, Murray CJ. A systematic analysis of global anemia burden from 1990 to 2010. *Blood* 2014; **123**: 615-624 [PMID: 24297872 DOI: 10.1182/blood-2013-06-508325]

29 **Boersma B**, Houwen RH, Blum WF, van Doorn J, Wit JM. Catch-up growth and endocrine changes in childhood celiac disease. Endocrine changes during catch-up growth. *Horm Res* 2002; **58** Suppl 1: 57-65 [PMID: 12373016 DOI: 10.1159/000064771]

30 **Luciano A**, Bolognani M, Di Falco A, Trabucchi C, Bonetti P, Castellarin A. [Catch-up growth and final height in celiac disease]. *Pediatr Med Chir* 2002; **24**: 9-12 [PMID: 11938689]

31 **Singh AD**, Singh P, Farooqui N, Strand T, Ahuja V, Makharia GK. Prevalence of celiac disease in patients with short stature: A systematic review and meta-analysis. *J Gastroenterol Hepatol* 2021; **36**: 44-54 [PMID: 32621396 DOI: 10.1111/jgh.15167]

32 **Elfström P**, Sundström J, Ludvigsson JF. Systematic review with meta-analysis: associations between coeliac disease and type 1 diabetes. *Aliment Pharmacol Ther* 2014; **40**: 1123-1132 [PMID: 25270960 DOI: 10.1111/apt.12973]

33 **Rubio-Tapia A**, Van Dyke CT, Lahr BD, Zinsmeister AR, El-Youssef M, Moore SB, Bowman M, Burgart LJ, Melton LJ 3rd, Murray JA. Predictors of family risk for celiac disease: a population-based study. *Clin Gastroenterol Hepatol* 2008; **6**: 983-987 [PMID: 18585974 DOI: 10.1016/j.cgh.2008.04.008]

34 **Bonamico M**, Ferri M, Mariani P, Nenna R, Thanasi E, Luparia RP, Picarelli A, Magliocca FM, Mora B, Bardella MT, Verrienti A, Fiore B, Uccini S, Megiorni F, Mazzilli MC, Tiberti C. Serologic and genetic markers of celiac disease: a sequential study in the screening of first degree relatives. *J Pediatr Gastroenterol Nutr* 2006; **42**: 150-154 [PMID: 16456406 DOI: 10.1097/01.mpg.0000189337.08139.83]

35 **Högberg L**, Fälth-Magnusson K, Grodzinsky E, Stenhammar L. Familial prevalence of coeliac disease: a twenty-year follow-up study. *Scand J Gastroenterol* 2003; **38**: 61-65 [PMID: 12608466 DOI: 10.1080/00365520310000456]

36 **Singh P**, Arora S, Lal S, Strand TA, Makharia GK. Risk of Celiac Disease in the First- and Second-Degree Relatives of Patients With Celiac Disease: A Systematic Review and Meta-Analysis. *Am J Gastroenterol* 2015; **110**: 1539-1548 [PMID: 26416192 DOI: 10.1038/ajg.2015.296]

37 **Kurppa K**, Salminiemi J, Ukkola A, Saavalainen P, Löytynoja K, Laurila K, Collin P, Mäki M, Kaukinen K. Utility of the new ESPGHAN criteria for the diagnosis of celiac disease in at-risk groups. *J Pediatr Gastroenterol Nutr* 2012; **54**: 387-391 [PMID: 22094901 DOI: 10.1097/MPG.0b013e3182407c6b]

38 **Kotze LM**, Brambila Rodrigues AP, Kotze LR, Nisihara RM. A Brazilian experience of the self transglutaminase-based test for celiac disease case finding and diet monitoring. *World J Gastroenterol* 2009; **15**: 4423-4428 [PMID: 19764094 DOI: 10.3748/wjg.15.4423]

39 **Weinstein WM**, Brow JR, Parker F, Rubin CE. The small intestinal mucosa in dermatitis herpetiformis. II. Relationship of the small intestinal lesion to gluten. *Gastroenterology* 1971; **60**: 362-369 [PMID: 5554078]

40 **Brow JR**, Parker F, Weinstein WM, Rubin CE. The small intestinal mucosa in dermatitis herpetiformis. I. Severity and distribution of the small intestinal lesion and associated malabsorption. *Gastroenterology* 1971; **60**: 355-361 [PMID: 5554077]

41 **Reunala T**, Hervonen K, Salmi T. Dermatitis Herpetiformis: An Update on Diagnosis and Management. *Am J Clin Dermatol* 2021; **22**: 329-338 [PMID: 33432477 DOI: 10.1007/s40257-020-00584-2]

42 **Persechino F**, Galli G, Persechino S, Valitutti F, Zenzeri L, Mauro A, Corleto VD, Parisi P, Ziparo C, Evangelisti M, Quatrale G, Di Nardo G. Skin Manifestations and Coeliac Disease in Paediatric Population. *Nutrients* 2021; **13** [PMID: 34684612 DOI: 10.3390/nu13103611]

43 **Mansikka E**, Hervonen K, Kaukinen K, Collin P, Huhtala H, Reunala T, Salmi T. Prognosis of Dermatitis Herpetiformis Patients with and without Villous Atrophy at Diagnosis. *Nutrients* 2018; **10** [PMID: 29783727 DOI: 10.3390/nu10050641]

44 **Green PHR**, Stavropoulos SN, Panagi SG, Goldstein SL, Mcmahon DJ, Absan H, Neugut AI. Characteristics of adult celiac disease in the USA: results of a national survey. *Am J Gastroenterol* 2001; **96**: 126-131 [PMID: 11197241 DOI: 10.1111/j.1572-0241.2001.03462.x]

45 **Collin P**, Huhtala H, Virta L, Kekkonen L, Reunala T. Diagnosis of celiac disease in clinical practice: physician's alertness to the condition essential. *J Clin Gastroenterol* 2007; **41**: 152-156 [PMID: 17245213 DOI: 10.1097/01.mcg.0000212618.12455.a8]

46 **Du Y**, Shan LF, Cao ZZ, Feng JC, Cheng Y. Prevalence of celiac disease in patients with Down syndrome: a meta-analysis. *Oncotarget* 2018; **9**: 5387-5396 [PMID: 29435186 DOI: 10.18632/oncotarget.23624]

47 **Sainsbury A**, Sanders DS, Ford AC. Meta-analysis: Coeliac disease and hypertransaminasaemia. *Aliment Pharmacol Ther* 2011; **34**: 33-40 [PMID: 21545472 DOI: 10.1111/j.1365-2036.2011.04685.x]

48 **Castillo NE**, Vanga RR, Theethira TG, Rubio-Tapia A, Murray JA, Villafuerte J, Bonder A, Mukherjee R, Hansen J, Dennis M, Kelly CP, Leffler DA. Prevalence of abnormal liver function tests in celiac disease and the effect of a gluten-free diet in the US population. *Am J Gastroenterol* 2015; **110**: 1216-1222 [PMID: 26150087 DOI: 10.1038/ajg.2015.192]

49 **Singh P**, Agnihotri A, Jindal G, Sharma PK, Sharma M, Das P, Gupta D, Makharia GK. Celiac disease and chronic liver disease: is there a relationship? *Indian J Gastroenterol* 2013; **32**: 404-408 [PMID: 23918040 DOI: 10.1007/s12664-013-0352-z]

50 **Ludvigsson JF**, Elfström P, Broomé U, Ekbom A, Montgomery SM. Celiac disease and risk of liver disease: a general population-based study. *Clin Gastroenterol Hepatol* 2007; **5**: 63-69.e1 [PMID: 17161656 DOI: 10.1016/j.cgh.2006.09.034]

51 **Lindgren S**, Sjöberg K, Eriksson S. Unsuspected coeliac disease in chronic 'cryptogenic' liver disease. *Scand J Gastroenterol* 1994; **29**: 661-664 [PMID: 7939405 DOI: 10.3109/00365529409092489]

52 **Kaukinen K**, Halme L, Collin P, Färkkilä M, Mäki M, Vehmanen P, Partanen J, Höckerstedt K. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. *Gastroenterology* 2002; **122**: 881-888 [PMID: 11910339 DOI: 10.1053/gast.2002.32416]

53 **Ratziu V**, Nourani M, Poynard T. Discussion on celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. *Gastroenterology* 2002; **123**: 2158-9; author reply 2159-60 [PMID: 12454882 DOI: 10.1053/gast.2002.37302]

54 **Wakim-Fleming J**, Pagadala MR, McCullough AJ, Lopez R, Bennett AE, Barnes DS, Carey WD. Prevalence of celiac disease in cirrhosis and outcome of cirrhosis on a gluten free diet: a prospective study. *J Hepatol* 2014; **61**: 558-563 [PMID: 24842303 DOI: 10.1016/j.jhep.2014.05.020]

55 **Haggård L**, Glimberg I, Lebwohl B, Sharma R, Verna EC, Green PHR, Ludvigsson JF. High prevalence of celiac disease in autoimmune hepatitis: Systematic review and meta-analysis. *Liver Int* 2021; **41**: 2693-2702 [PMID: 34219350 DOI: 10.1111/liv.15000]

56 **Irvine AJ**, Chey WD, Ford AC. Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis. *Am J Gastroenterol* 2017; **112**: 65-76 [PMID: 27753436 DOI: 10.1038/ajg.2016.466]

57 **Al-Abachi KT**. Screening for Celiac Disease in Patients with Irritable Bowel Syndrome Fulfilling Rome III Criteria. J Coloproctology 2022; 42: 20-24 [DOI: 10.1055/s-0041-1736645]

58 **Mazure R**, Vazquez H, Gonzalez D, Mautalen C, Pedreira S, Boerr L, Bai JC. Bone mineral affection in asymptomatic adult patients with celiac disease. *Am J Gastroenterol* 1994; **89**: 2130-2134 [PMID: 7977227]

59 **Kemppainen T**, Kröger H, Janatuinen E, Arnala I, Kosma VM, Pikkarainen P, Julkunen R, Jurvelin J, Alhava E, Uusitupa M. Osteoporosis in adult patients with celiac disease. *Bone* 1999; **24**: 249-255 [PMID: 10071918 DOI: 10.1016/s8756-3282(98)00178-1]

60 **Ganji R**, Moghbeli M, Sadeghi R, Bayat G, Ganji A. Prevalence of osteoporosis and osteopenia in men and premenopausal women with celiac disease: a systematic review. *Nutr J* 2019; **18**: 9 [PMID: 30732599 DOI: 10.1186/s12937-019-0434-6]

61 **Olmos M**, Antelo M, Vazquez H, Smecuol E, Mauriño E, Bai JC. Systematic review and meta-analysis of observational studies on the prevalence of fractures in coeliac disease. *Dig Liver Dis* 2008; **40**: 46-53 [PMID: 18006396 DOI: 10.1016/j.dld.2007.09.006]

62 **Mosca C**, Thorsteinsdottir F, Abrahamsen B, Rumessen JJ, Händel MN. Newly Diagnosed Celiac Disease and Bone Health in Young Adults: A Systematic Literature Review. *Calcif Tissue Int* 2022; **110**: 641-648 [PMID: 34978602 DOI: 10.1007/s00223-021-00938-w]

63 **Laszkowska M**, Mahadev S, Sundström J, Lebwohl B, Green PHR, Michaelsson K, Ludvigsson JF. Systematic review with meta-analysis: the prevalence of coeliac disease in patients with osteoporosis. *Aliment Pharmacol Ther* 2018; **48**: 590-597 [PMID: 29984519 DOI: 10.1111/apt.14911]

64 **Singh AD**, Ellias S, Singh P, Ahuja V, Makharia GK. The Prevalence of the Celiac Disease in Patients with Dyspepsia: A Systematic Review and Meta-Analysis. *Dig Dis Sci* 2021; Epub ahead of print [PMID: 34268659 DOI: 10.1007/s10620-021-07142-8]

65 **Ford AC**, Ching E, Moayyedi P. Meta-analysis: yield of diagnostic tests for coeliac disease in dyspepsia. *Aliment Pharmacol Ther* 2009; **30**: 28-36 [PMID: 19416130 DOI: 10.1111/j.1365-2036.2009.04008.x]

66 **Eliakim R**, Sherer DM. Celiac disease: fertility and pregnancy. *Gynecol Obstet Invest* 2001; **51**: 3-7 [PMID: 11150866 DOI: 10.1159/000052881]

67 **Gasbarrini A**, Torre ES, Trivellini C, De Carolis S, Caruso A, Gasbarrini G. Recurrent spontaneous abortion and intrauterine fetal growth retardation as symptoms of coeliac disease. *Lancet* 2000; **356**: 399-400 [PMID: 10972376 DOI: 10.1016/S0140-6736(00)02535-6]

68 **Bennett SI,** Gupta A. Successful Pregnancy on a Gluten-Free Diet in a Woman with Seven Miscarriages and Nonceliac Gluten Sensitivity. AACE Clin Case Rep 2018; 4: e443-e446 [DOI: 10.4158/ACCR-2018-0095]

69 **Alecsandru D**, López-Palacios N, Castaño M, Aparicio P, García-Velasco JA, Núñez C. Exploring undiagnosed celiac disease in women with recurrent reproductive failure: The gluten-free diet could improve reproductive outcomes. *Am J Reprod Immunol* 2020; **83**: e13209 [PMID: 31709662 DOI: 10.1111/aji.13209]

70 **Singh P**, Arora S, Lal S, Strand TA, Makharia GK. Celiac Disease in Women With Infertility: A Meta-Analysis. *J Clin Gastroenterol* 2016; **50**: 33-39 [PMID: 25564410 DOI: 10.1097/MCG.0000000000000285]

71 **Tersigni C**, Castellani R, de Waure C, Fattorossi A, De Spirito M, Gasbarrini A, Scambia G, Di Simone N. Celiac disease and reproductive disorders: meta-analysis of epidemiologic associations and potential pathogenic mechanisms. *Hum Reprod Update* 2014; **20**: 582-593 [PMID: 24619876 DOI: 10.1093/humupd/dmu007]

72 **Glimberg I**, Haggård L, Lebwohl B, Green PHR, Ludvigsson JF. The prevalence of celiac disease in women with infertility-A systematic review with meta-analysis. *Reprod Med Biol* 2021; **20**: 224-233 [PMID: 33850456 DOI: 10.1002/rmb2.12374]

73 **Curione M**, Barbato M, De Biase L, Viola F, Lo Russo L, Cardi E. Prevalence of coeliac disease in idiopathic dilated cardiomyopathy. *Lancet* 1999; **354**: 222-223 [PMID: 10421311 DOI: 10.1016/s0140-6736(99)01501-9]

74 **De Bem RS**, Da Ro Sa Utiyama SR, Nisihara RM, Fortunato JA, Tondo JA, Carmes ER, Souza RA, Pisani JC, Amarante HM. Celiac disease prevalence in Brazilian dilated cardiomyopathy patients. *Dig Dis Sci* 2006; **51**: 1016-1019 [PMID: 16758314 DOI: 10.1007/s10620-006-9337-4]

75 **Menezes TM**, Motta ME. Celiac disease prevalence in children and adolescents with myocarditis and dilated cardiomiopathy. *J Pediatr (Rio J)* 2012; **88**: 439-442 [PMID: 23093320 DOI: 10.2223/JPED.2219]

76 **Vizzardi E**, Lanzarotto F, Carabellese N, Mora A, Bertolazzi S, Benini F, Nodari S, Dei Cas L, Lanzini A. Lack of association of coeliac disease with idiopathic and ischaemic dilated cardiomyopathies. *Scand J Clin Lab Invest* 2008; **68**: 692-695 [PMID: 18609114 DOI: 10.1080/00365510802085370]

77 **Zahmatkeshan M**, Fallahpoor M, Amoozgar H. Prevalence of celiac disease in children with idiopathic dilated cardiomyopathy. *Iran J Pediatr* 2014; **24**: 587-592 [PMID: 25793066]

78 **Roy A**, Laszkowska M, Sundström J, Lebwohl B, Green PH, Kämpe O, Ludvigsson JF. Prevalence of Celiac Disease in Patients with Autoimmune Thyroid Disease: A Meta-Analysis. *Thyroid* 2016; **26**: 880-890 [PMID: 27256300 DOI: 10.1089/thy.2016.0108]

79 **Işıkay S**, Kocamaz H. Prevalence of celiac disease in children with idiopathic epilepsy in southeast Turkey. *Pediatr Neurol* 2014; **50**: 479-481 [PMID: 24656466 DOI: 10.1016/j.pediatrneurol.2014.01.021]

80 **Julian T**, Hadjivassiliou M, Zis P. Gluten sensitivity and epilepsy: a systematic review. *J Neurol* 2019; **266**: 1557-1565 [PMID: 30167878 DOI: 10.1007/s00415-018-9025-2]

81 **Vieira C**, Jatobá I, Matos M, Diniz-Santos D, Silva LR. Prevalence of celiac disease in children with epilepsy. *Arq Gastroenterol* 2013; **50**: 290-296 [PMID: 24474232 DOI: 10.1590/S0004-28032013000400010]

82 **Bürk K**, Farecki ML, Lamprecht G, Roth G, Decker P, Weller M, Rammensee HG, Oertel W. Neurological symptoms in patients with biopsy proven celiac disease. *Mov Disord* 2009; **24**: 2358-2362 [PMID: 19845007 DOI: 10.1002/mds.22821]

83 **Hadjivassiliou M**, Duker AP, Sanders DS. Gluten-related neurologic dysfunction. *Handb Clin Neurol* 2014; **120**: 607-619 [PMID: 24365341 DOI: 10.1016/B978-0-7020-4087-0.00041-3]

84 **Hadjivassiliou M**, Aeschlimann P, Sanders DS, Mäki M, Kaukinen K, Grünewald RA, Bandmann O, Woodroofe N, Haddock G, Aeschlimann DP. Transglutaminase 6 antibodies in the diagnosis of gluten ataxia. *Neurology* 2013; **80**: 1740-1745 [PMID: 23576621 DOI: 10.1212/WNL.0b013e3182919070]

85 **Fousekis FS**, Beka ET, Mitselos IV, Milionis H, Christodoulou DK. Thromboembolic complications and cardiovascular events associated with celiac disease. *Ir J Med Sci* 2021; **190**: 133-141 [PMID: 32691305 DOI: 10.1007/s11845-020-02315-2]

86 **Lin CY**, Wang MJ, Tse W, Pinotti R, Alaedini A, Green PHR, Kuo SH. Serum antigliadin antibodies in cerebellar ataxias: a systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry* 2018; **89**: 1174-1180 [PMID: 29866704 DOI: 10.1136/jnnp-2018-318215]

87 **Hadjivassiliou M**, Davies-Jones GA, Sanders DS, Grünewald RA. Dietary treatment of gluten ataxia. *J Neurol Neurosurg Psychiatry* 2003; **74**: 1221-1224 [PMID: 12933922 DOI: 10.1136/jnnp.74.9.1221]

88 **Hadjivassiliou M**, Sanders DD, Aeschlimann DP. Gluten-related disorders: gluten ataxia. *Dig Dis* 2015; **33**: 264-268 [PMID: 25925933 DOI: 10.1159/000369509]

89 **Hadjivassiliou M**, Grünewald R, Sharrack B, Sanders D, Lobo A, Williamson C, Woodroofe N, Wood N, Davies-Jones A. Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics. *Brain* 2003; **126**: 685-691 [PMID: 12566288 DOI: 10.1093/brain/awg050]

90 **Pellecchia MT**, Scala R, Filla A, De Michele G, Ciacci C, Barone P. Idiopathic cerebellar ataxia associated with celiac disease: lack of distinctive neurological features. *J Neurol Neurosurg Psychiatry* 1999; **66**: 32-35 [PMID: 9886447 DOI: 10.1136/jnnp.66.1.32]

91 **Bushara KO**, Goebel SU, Shill H, Goldfarb LG, Hallett M. Gluten sensitivity in sporadic and hereditary cerebellar ataxia. *Ann Neurol* 2001; **49**: 540-543 [PMID: 11310636]

92 **El-Hodhod MA**, El-Agouza IA, Abdel-Al H, Kabil NS, Bayomi KA. Screening for celiac disease in children with dental enamel defects. *ISRN Pediatr* 2012; **2012**: 763783 [PMID: 22720168 DOI: 10.5402/2012/763783]

93 **Martelossi S**, Zanatta E, Del Santo E, Clarich P, Radovich P, Ventura A. Dental enamel defects and screening for coeliac disease. *Acta Paediatr Suppl* 1996; **412**: 47-48 [PMID: 8783757 DOI: 10.1111/j.1651-2227.1996.tb14249.x]

94 **Alsadat FA**, Alamoudi NM, El-Housseiny AA, Felemban OM, Dardeer FM, Saadah OI. Oral and dental manifestations of celiac disease in children: a case-control study. *BMC Oral Health* 2021; **21**: 669 [PMID: 34965875 DOI: 10.1186/s12903-021-01976-4]

95 **Zoumpoulakis M**, Fotoulaki M, Topitsoglou V, Lazidou P, Zouloumis L, Kotsanos N. Prevalence of Dental Enamel Defects, Aphthous-Like Ulcers and Other Oral Manifestations in Celiac Children and Adolescents: A Comparative Study. *J Clin Pediatr Dent* 2019; **43**: 274-280 [PMID: 31283894 DOI: 10.17796/1053-4625-43.4.9]

96 **Chou R**, Bougatsos C, Blazina I, Mackey K, Grusing S, Selph S. Screening for Celiac Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA* 2017; **317**: 1258-1268 [PMID: 28350935 DOI: 10.1001/jama.2016.10395]

97 **Singh P**, Singh A, Silvester JA, Sachdeva V, Chen X, Xu H, Leffler DA, Ahuja V, Duerksen DR, Kelly CP, Makharia GK. Inter- and Intra-assay Variation in the Diagnostic Performance of Assays for Anti-tissue Transglutaminase in 2 Populations. *Clin Gastroenterol Hepatol* 2020; **18**: 2628-2630 [PMID: 31546060 DOI: 10.1016/j.cgh.2019.09.018]

98 **Naiyer AJ**, Hernandez L, Ciaccio EJ, Papadakis K, Manavalan JS, Bhagat G, Green PH. Comparison of commercially available serologic kits for the detection of celiac disease. *J Clin Gastroenterol* 2009; **43**: 225-232 [PMID: 18724250 DOI: 10.1097/MCG.0b013e31816200e5]

99 **Husby S**, Koletzko S, Korponay-Szabó I, Kurppa K, Mearin ML, Ribes-Koninckx C, Shamir R, Troncone R, Auricchio R, Castillejo G, Christensen R, Dolinsek J, Gillett P, Hróbjartsson A, Koltai T, Maki M, Nielsen SM, Popp A, Størdal K, Werkstetter K, Wessels M. European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020. *J Pediatr Gastroenterol Nutr* 2020; **70**: 141-156 [PMID: 31568151 DOI: 10.1097/MPG.0000000000002497]

100 **Singh P**, Arora A, Strand TA, Leffler DA, Mäki M, Kelly CP, Ahuja V, Makharia GK. Diagnostic Accuracy of Point of Care Tests for Diagnosing Celiac Disease: A Systematic Review and Meta-Analysis. *J Clin Gastroenterol* 2019; **53**: 535-542 [PMID: 29912751 DOI: 10.1097/MCG.0000000000001081]

**Footnotes**

**Conflict-of-interest statement:** There are no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 31, 2021

**First decision:** January 27, 2022

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): D


Grade E (Poor): 0

**P-Reviewer:** Deng K, China; Liu C, China **S-Editor:** Zhang H **L-Editor:** Kerr C **P-Editor:** Zhang H

**Figure Legends**

****

**Figure 1 Summary of the prevalence of celiac disease in various associated conditions based on the various systems.** The reported prevalence per the present literature, the studies may be limited by the number and quality of studies available.

****

**Figure 2 A screening algorithm for patients with suspected celiac disease.** EGD: Esophagogastroduodenoscopy; ULN: Upper limit of normal.

**Table 1 The pooled prevalence of celiac disease in various conditions**

|  |  |  |
| --- | --- | --- |
| **Condition** | **Pooled prevalence (%)** | **95% CI** |
| Definite indications | | |
| Chronic diarrhea[18]a | 3-10 | NA |
| Iron deficiency anemia[14] | 3.2 | 2.6-3.9 |
| Short stature[32] |  |  |
| All-cause | 7.4 | 4.7-10.6 |
| Idiopathic | 11.6 | 4.1-22.2 |
| Type 1 diabetes[33] | 6 | 5-6.9 |
| Pediatric age group | 6.2 | 6.1-6.3 |
| Adults | 2.7 | 2.1-2.3 |
| First-degree relatives[37] | 7.5 | 6.3-8.8 |
| Dermatitis herpetiformis[45,46]a | 9.8-17 | NA |
| Down syndrome[47] | 5.8 | 4.7-7.2 |
| Probable indications | | |
| Cryptogenic hypertransaminesemia[48] | 5.9 | 3.1-9.34 |
| Autoimmune hepatitis[56] | 3.5 | 1.6-5.3 |
| Irritable bowel syndrome[57] | 3.3 | 2.3-4.5 |
| Diarrhea predominant IBS | 5.4 | 3.3-7.8 |
| Constipation predominant IBS | 1.8 | 0.9-3.0 |
| Mixed-IBS | 3.1 | 1.7-5.1 |
| Osteoporosis[64] | 1.6 | 1.1-2.0 |
| Possible indications | | |
| Dyspepsia[65] | 1.4 | 0.9-1.8 |
| Women with infertility[73] |  |  |
| All-cause infertility | 0.7 | 0.2-1.2 |
| Idiopathic infertility | 0.6 | 0.0-1.6 |
| Idiopathic cardiomyopathy[74-78]a | 0-5.7 |  |
| Autoimmune thyroid disease[79] | 1.6 | 1.3-1.9 |
| Hypothyroidism | 1.4 | 1-1.9 |
| Hyperthyroidism | 2.6 | 0.7-4.4 |
| Idiopathic epilepsy[81] | 2.1 | 1.6-2.6 |
| Idiopathic cerebellar ataxia[87] | 4.3 | 3.1-5.9 |
| Dental enamel defects[93,94] | 15 | 11-21 |

aExpressed as a range.

CI: Confidence interval; IBS: irritable bowel syndrome; NA: Not available.

**Table 2 The sensitivity and specificity of the screening tests for celiac disease**

|  |  |  |
| --- | --- | --- |
| **Test** | **Sensitivity** | **Specificity** |
| Anti-tissue transglutaminase antibody[97] | 92.8% (95%CI: 90.3-94.8) | 97.9% (95%CI: 96.4- 98.8) |
| Anti-endomysial antibody[97] | 73% (95%CI: 61-83) | 99.0% (95%CI 98.0-99.0) |
| Deamidated gliadin peptide antibodies[97] | 87.8% (95%CI: 85.6-89.9) | 94.1% (95%CI: 92.5-95.5) |
| Point-of care tests (107) |  |  |
| Anti-anti-tissue transglutaminase antibody + Anti-gliadin antibody | 94.0% (95%CI: 89.9-96.5) | 94.4% (95%CI: 90.9-96.5) |
| IgA anti-tissue transglutaminase antibody | 90.5% (95%CI: 82.3-95.1) | 94.8% (95%CI: 92.5-96.4) |